WHAT IS CLAIMED IS:

1. An oral pharmaceutical composition comprising a compound of Formula I or a pharmaceutically acceptable salt thereof:



Formula I;

wherein

each R is independently selected from H, halogen, substituted or unsubstituted C_{1-4} alkyl, and substituted or unsubstituted C_{1-4} alkoxy;

A is selected from H, substituted or unsubstituted C_{1-4} alkyl, substituted or unsubstituted phenyl, substituted or unsubstituted (C_{1-4} alkyl)phenyl, substituted or unsubstituted 5-6 membered heteroaryl containing one or more heteroatoms selected from N, O, and S, substituted or unsubstituted heterocyclyl containing one or more heteroatom selected from N, O, and S, and substituted or unsubstituted C_{1-4} alkoxycarbonyl; wherein the substituents are selected from halogen, substituted or unsubstituted C_{1-4} alkyl, and substituted or unsubstituted C_{1-4} alkoxy;

n is 0, 1, 2, or 3; and

* denotes a stereocenter;

and one or more pharmaceutically acceptable excipients,

wherein the compound of Formula I has a particle size D_{90} of less than about 200 μm.

2. The oral pharmaceutical composition of claim 1, wherein the compound of Formula I is a compound of Formula IA, IB, IC, ID or IE:



Formula IA;



Formula IB;



Formula IC;



Formula ID;



Formula IE.

3. The oral pharmaceutical composition of claim 1 or claim 2, wherein the compound of Formula I is a compound of Formula IA:



Formula IA.

4. The oral pharmaceutical composition of any one of claims 1-3, wherein the compound of Formula I has a particle size D_{90} of between about 60 µm and about 100 µm.

5. The oral pharmaceutical composition of any one of claims 1-3, wherein the compound of Formula I has a particle size D_{90} of between about 2.0 µm and about 150 µm.

6. The oral pharmaceutical composition of any one of claims 1-5, wherein the compound of Formula I represents less than about 75% w/w of the total weight of the composition.

7. The oral pharmaceutical composition of any one of claims 1-5, wherein the composition is a tablet or a capsule.

8. The oral pharmaceutical composition of any one of claims 1-7, wherein the composition is a solid, and at least 90% of the compound of Formula I in the composition is released within 30 minutes when tested according to USP II (paddle method) at 100 rpm and 37.0 ± 0.5° C in 900 mL of (i) simulated gastric fluid (without pepsin) at pH 1.2, (ii) 0.01 N HCl aqueous solution containing 1% sodium lauryl sulfate, (iii) 0.1 N HCl aqueous solution containing 1% sodium lauryl sulfate, (iv) aqueous pH 4.5 acetate solution and 1% sodium lauryl sulfate, or (v) aqueous pH 6.8 phosphate solution and 1% sodium lauryl sulfate.

9. The oral pharmaceutical composition of any one of claims 1-6, wherein the composition is a solution or a suspension.

10. A compressed tablet comprising a compound of Formula IA or a pharmaceutically acceptable salt thereof



Formula IA

dispersed in

(a) a non-ionic, water dispersible surfactant;

(b) colloidal silicon dioxide;

(c) crospovidone; and

(d) spray-dried (i) D-mannitol, (ii) xylitol, (iii) microcrystalline cellulose, (iv) crospovidone, and (v) dibasic calcium phosphate;

wherein the compound of Formula IA has a particle size D_{90} of less than about 200 μm.

11. The tablet of claim 10, wherein the non-ionic, water dispersible surfactant is a mixture of lauroyl polyoxyl-32 glycerides and PEG 6000.

12. An oral aqueous suspension comprising:

(a) a compound of Formula IA or a pharmaceutically acceptable salt thereof



Formula IA; and

(b) 2-hydroxypropyl beta-cyclodextrin.

13. The oral aqueous suspension of claim 12, wherein the ratio of the compound of Formula IA to 2-hydroxypropyl beta-cyclodextrin is about 1:5 to about 1:10.

14. Use of the oral pharmaceutical composition according to any one of claims 1-9, the tablet of claim 10 or 11, or the oral aqueous suspension of claim 12 or 13, in the manufacture of a medicament for treating diabetes or obesity.